Continuous renal replacement therapy (CRRT) Urological and Genital Diseases Renal replacement
Conditions
Interventions
Please note that the first patient was recruited to this trial in November 2005 and the last patient completed the study in June 2007.
Each patient will be treated by maximum 4 filter
Sponsors
Gambro Industries (France)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients requiring CRRT 2. Patients aged 18 and over 3. Patients weighing 30-120 kg 4. Patients having signed a written consent (informed consent) to participate in the study or, in case the patient is unable to understand and/or sign the consent form, written consent from a relative or, failing which, a person of trust
Exclusion criteria
Exclusion criteria: 1. Suspicion of heparin-induced thrombocytopenia 2. Pregnancy 3. Patients requiring therapeutic anticoagulation for other indications e.g. valvular surgery or extracorporeal ventricular assist devices 4. Patients under guardianship 5. Patients anticipated to require transportation outside the unit for diagnostic or therapeutic procedures in the coming first week. These patients can eventually be included in a later more stable phase. 6. Current enrolment in another trial which could impact the successful completion of this study 7. Unconscious patients for whom no relative or person of trust can give consent for treatment. In the absence of any relative or person of trust, the patient in question cannot be included in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is filter lifespan, defined as the time period between patient?s connection and filter disconnection. Filter clotting will be detected by following transmembrane pressure (TMP) and Filter Pressure Drop (FPD). If the pressure changes are only temporary, treatment is continued. If they are permanent, the filter is discontinued with blood return. | — |
Secondary
| Measure | Time frame |
|---|---|
| Follow up of treatment safety: thrombopenia, bleeding episodes, transfusion requirement, treatment instability due to frequent filter changes. | — |
Countries
Belgium
Outcome results
None listed